CRNX AI Price Prediction
Track CRNX's AI-powered predictions, market trends, and investment insights.
Mock Tradesimulated, no real money
You don't hold CRNX in your mock portfolio yet.
Track CRNX's AI-powered predictions, market trends, and investment insights.
You don't hold CRNX in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedCrinetics Pharmaceuticals is currently unprofitable, as reflected in its negative EPS and PE ratio. The lack of positive earnings suggests the company is still in an investment and development phase rather than a cash-generating phase. From a pure financial-performance standpoint, this positions the stock as higher risk and dependent on future execution and clinical or commercial milestones.
The stock trades at $34.47, below its 200-day moving average of $41.65, and has declined 6.3% over the last month, indicating recent weakness and a bearish intermediate trend. Trading below the 200-day moving average generally signals that the market is cautious or reassessing the company’s outlook. Without evidence of oversold conditions (e.g., RSI not provided), the technical picture leans negative in the near term.
Alternative data for Crinetics Pharmaceuticals show modest but steady engagement and hiring, with no signs of sharp deterioration or aggressive expansion. Web traffic is moderate and job openings are stable, suggesting a steady-state operating posture rather than a major ramp-up or contraction. LinkedIn follower growth stands out as relatively stronger than other social channels, hinting at growing professional and industry interest.
Overall, the picture for Crinetics Pharmaceuticals is neutral: financials and technicals are currently bearish, but alternative data suggest a stable underlying business with gradually rising professional interest. The stock appears to be in a consolidation or reassessment phase where future clinical, regulatory, or partnership milestones will likely drive the next major move. Investors are effectively betting on long-term pipeline success rather than near-term earnings strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Crinetics Pharmaceuticals (CRNX) is trading at $34.63 on NASDAQ, posting a sharp single-session gain of 4.7% on volume of over 1.05 million shares — notably elevated activity for a clinical-stage biotech with a $3.7 billion market capitalization. The company is advancing Paltusotine, an oral nonpeptide somatostatin receptor type 2 agonist that has completed Phase III trials for acromegaly and Phase II for carcinoid syndrome and neuroendocrine tumors. Today's price movement suggests near-term positive sentiment, though it does not yet reflect a confirmed directional trend.
TrendEdge's AI model assigns CRNX a score of 5 out of 10 — a neutral reading that reflects a balance of opportunity and uncertainty. For a clinical-stage company, a mid-range score typically signals that pipeline progress is acknowledged by the market, but binary clinical or regulatory outcomes create significant forecast volatility. Paltusotine's completed Phase III data for acromegaly represents a key value driver already partially priced in, while earlier-stage assets like CRN04777 add optionality without near-term revenue visibility. The AI score suggests neither a strong accumulation nor distribution signal at current levels.
Investors should monitor regulatory decisions around Paltusotine's acromegaly indication as the primary near-term catalyst, with any FDA action representing a potential step-change in valuation. Expansion into carcinoid syndrome and NETs could broaden the commercial opportunity meaningfully. Key risks include clinical setbacks across the pipeline, cash burn typical of pre-revenue biotechs, and market sensitivity to broader risk-off sentiment. The neutral AI score of 5/10 warrants a watchlist posture rather than a conviction position until a clearer catalyst materializes.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
19,607
Twitter Followers
1,074
Instagram Followers
179
LinkedIn Followers
52,227
Job Postings
40
LinkedIn Employees
613
News Mentions
0
Key Metrics
